Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 6 publications
Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivolumab alone in patients with advanced or metastatic solid tumors with high TMB.
Journal: Journal for immunotherapy of cancer
Published: September 24, 2023
Fibrotic activity quantified in serum by measurements of type III collagen pro-peptides can be used for prognosis across different solid tumor types.
Journal: Cellular and molecular life sciences : CMLS
Published: December 07, 2021
Bioinformatic Methods and Bridging of Assay Results for Reliable Tumor Mutational Burden Assessment in Non-Small-Cell Lung Cancer.
Journal: Molecular diagnosis & therapy
Published: June 29, 2019
First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: February 21, 2019
After 50 years, a personal reflection on the development of internal thoracic artery (ITA) grafting.
After 50 years, a personal reflection on the development of internal thoracic artery (ITA) grafting.
Journal: Annals of cardiothoracic surgery
Published: December 04, 2018
Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.
Journal: The New England journal of medicine
Published: April 17, 2018
Showing 1-6 of 6
Last Updated: 09/26/2026